TrialProceedings of the National Academy of Sciences of the United States of America2004

Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant.

Qiyuan Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.